



# A New Horizon in Pneumonia Risk Prediction for ICI-P Patients: The Non-Imaging Based Model

Ruikai Lin<sup>1,2,#</sup>, Zhixuan Jing<sup>1,#</sup>, Diankang Huang<sup>1</sup>, Isabel Tan Shiyu<sup>1</sup>, Na Bai<sup>3,\*</sup>

Yong Loo Lin School of Medicine, National University of Singapore
 Institute for Infocomm Research (I2R), A\*STAR, Singapore
 Shanghai United Imaging Intelligence Co., Ltd., China

## **Background**






21st MDBS-14th BHE 18-20 December 2023 Hong Kong, China

"Emerging Bio-optical and Biosensing Technologies for Future Health"

#### Lung cancer incidence rate

- In 2020, lung cancer accounted for 11.4% of all cancer diagnoses
- Incidence rate is the second highest

Estimated number of new cases in 2020, World, both sexes, all ages








#### ICI-P Incidence rate and death rate

• The incidence rate of ICI-P in clinical practice can reach up to 12.4%



The imaging changes associated with ICI-P, characterized by their delay, complexity, and non-specific nature, are easily confused with other respiratory diseases, increasing the difficulty of their diagnose. Therefore, a tool that can predict and detect ICI-P early is crucial.

## Previous Work — CT-based workflow







21st MDBS-14th BHE 18-20 December 2023 Hong Kong, China

"Emerging Bio-optical and Biosensing Technologies for

State-of-the-art (SOTA) Positive Risk Prediction Model <sup>1</sup>








AUC = **0.91** 











CT Score =  $\mu \times \sum_{i=1}^{i=n} (i \times p(i))$ 

<sup>&</sup>lt;sup>1</sup> Cheng, M.\*, Lin, R.\*, Bai, N.\*, Zhang, Y., Wang, H., Guo, M., ... & Zhao, Y. (2023). Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer. Clinical Radiology, 78(5), e377-e385.


## Is CT scan compulsory for early detection?





#### **Research Aims**

- Develop a risk prediction model for early detection of ICI-P W/O Medical
   Imaging and quantify contributions of risk factors.
- Provides CT-based auxiliary diagnostic methods for ICI-P, including lesion segmentation, quantitative analysis and 3D reconstruction. The calculated lesion volume ratio (LVR) is also used to train the non-imaging prediction models. Draw on the idea of human-in-the-loop and continue to enhance the accuracy and robustness of proposed workflow using data from new intake patients.
- Construct a model for predicting lesion volume ratio (LVR), determining the severity (G1-G5) according to ASCO critieria.





### **Dataset & Feature Selection**





#### **Preprocessing Pipeline**





• Example for 5 continuous features


## **Segmentation & Quantification**






Hong Kong, China


"Emerging Bio-optical and Biosensing Technologies for Future Health".



Lung parenchyma annotation



ICI-P lesion annotation




Human-	-in-the-	loop	P
--------	----------	------	---

	32x128x128x128 (1x0.77x0.77)
3D full res. U-Net	64x64x64x64 (2x1.54x1.54)  128x32x32x32 (4x3.08x3.08)  256x16x16x16 (8x6.16x6.16)  2,2,2  (14x3.08x3.08)  256x16x16x16 (16x12.3x12.3)  320x4x4x4 (32x24.6x24.6)

Region	Dice score
Left Lung	0.95+
Right Lung	0.99+
ICI-P	0.71+





3D reconstruction


*V*(*ICIP Lesion*) Lesion Volume Ratio =  $V(Lung\ Parenchyma)$ 

## **Enhanced Nomogram**





 $+ 0.0027 \times PLR$ 




## **Our Workflow**








"Emerging Bio-optical and Biosensing Technologies for



















**Potential patients are** advised to undergo CT examination as soon as possible

## **Experimental Results**






21st MDBS-14th BHE 18-20 December 2023 Hong Kong, China


"Emerging Bio-optical and Biosensing Technologies for Future Health"


#### **Comparative Experiment**





From the table, our workflow shows the best performance in recall, F1 and AUC, indicating its effectiveness.

## Model Evaluation













## Thanks for attention!

Q&A Contact: rlin@u.nus.edu







